Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 12 (April 20), 2005: pp. 2726-2734
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.10.024
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Low, J. A.
Right arrow Articles by Swain, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Low, J. A.
Right arrow Articles by Swain, S. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer

Jennifer A. Low, Suparna B. Wedam, James J. Lee, Arlene W. Berman, Adam Brufsky, Sherry X. Yang, Marianne S. Poruchynsky, Seth M. Steinberg, Nitin Mannan, Tito Fojo, Sandra M. Swain

From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Magee-Women's Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Address reprint requests to Sandra M. Swain, MD, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889-5015; e-mail: swains{at}mail.nih.gov

PURPOSE: Ixabepilone (BMS-247550) is an epothilone B analog that stabilizes microtubules and has antitumor activity in taxane-refractory patients in phase I studies. In a phase II trial, we evaluated the efficacy and safety of ixabepilone in women with metastatic and locally advanced breast cancer.

PATIENTS AND METHODS: Breast cancer patients with measurable disease who had paclitaxel and/or docetaxel as prior neoadjuvant, adjuvant, or metastatic therapy were treated with ixabepilone at 6 mg/m2/d intravenously on days 1 through 5 every 3 weeks. Levels of glutamate (glu) -terminated and acetylated {alpha}-tubulin, markers of microtubule stabilization, were detected by Western blot and by immunohistochemistry in a subset of matched pre- and post-treatment tumor biopsies.

RESULTS: Thirty-seven patients received 153 cycles of ixabepilone. The best responses were a complete response in one patient (3%), partial responses in seven patients (19%), and stable disease in 13 patients (35%). Grade 3 and 4 toxicities included neutropenia (35%), febrile neutropenia (14%), fatigue (14%), diarrhea (11%), nausea/vomiting (5%), myalgia/arthralgia (3%), and sensory neuropathy (3%). Two patients were removed from study because of prolonged grade 2 or 3 neurotoxicity, and three patients were removed from study for other grade 3 and 4 nonhematologic toxicities. Compared with baseline levels, levels of both glu-terminated and acetylated {alpha}-tubulin were increased in tumor biopsies performed after ixabepilone therapy.

CONCLUSION: An objective response was seen in 22% of the patients in a population who had been previously treated with a taxane. Sensory neuropathy was mild with grade 3 neurotoxicity rarely seen. Microtubule stabilization occurred in tumor biopsies after treatment with ixabepilone.

Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004 (preliminary portions of the study, abstract 545).

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith, E. Tan-Chiu, J. Wright, A. R. Tan, N. A. DaCosta, E. Chuang, et al.
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
J. Clin. Oncol., June 20, 2009; 27(18): 2954 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
L. Boehnke Michaud
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer
Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106.
[Abstract] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. D. Reed, Y. Li, K. J. Anstrom, and K. A. Schulman
Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., May 1, 2009; 27(13): 2185 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. A. Yardley
Proactive Management of Adverse Events Maintains the Clinical Benefit of Ixabepilone
Oncologist, May 1, 2009; 14(5): 448 - 455.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G. G. Steger, A. Makhson, S. Tjulandin, H. Ludwig, M. Verrill, et al.
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
J. Clin. Oncol., February 1, 2009; 27(4): 526 - 534.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. C. Widemann, W. Goodspeed, A. Goodwin, T. Fojo, F. M. Balis, and E. Fox
Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors
J. Clin. Oncol., February 1, 2009; 27(4): 550 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Dumontet, M. A. Jordan, and F. F.Y. Lee
Ixabepilone: targeting {beta}III-tubulin expression in taxane-resistant malignancies
Mol. Cancer Ther., January 1, 2009; 8(1): 17 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Y.F. Lee, K. L. Covello, S. Castaneda, D. R. Hawken, D. Kan, A. Lewin, M.-L. Wen, R.-P. Ryseck, C. R. Fairchild, J. Fargnoli, et al.
Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models
Clin. Cancer Res., December 15, 2008; 14(24): 8123 - 8131.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Plummer, P. Woll, D. Fyfe, A. V. Boddy, M. Griffin, P. Hewitt, J. Carmichael, F. Namouni, M. Cohen, and M. Verrill
A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
Clin. Cancer Res., December 15, 2008; 14(24): 8288 - 8294.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Rivera, J. Lee, and A. Davies
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Oncologist, December 1, 2008; 13(12): 1207 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. G. Morris and M. N. Fornier
Microtubule Active Agents: Beyond the Taxane Frontier
Clin. Cancer Res., November 15, 2008; 14(22): 7167 - 7172.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Goodin
Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2017 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. R. Tan and D. L. Toppmeyer
Ixabepilone in Metastatic Breast Cancer: Complement or Alternative to Taxanes?
Clin. Cancer Res., November 1, 2008; 14(21): 6725 - 6729.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Bhushan and C. M Walko
Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer
Ann. Pharmacother., September 1, 2008; 42(9): 1252 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Goodin
Novel cytotoxic agents: Epothilones
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al.
The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. J. Lee and S. M. Swain
The Epothilones: Translating from the Laboratory to the Clinic
Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Vahdat
Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms
Oncologist, March 1, 2008; 13(3): 214 - 221.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. S. Thomas, H. L. Gomez, R. K. Li, H.-C. Chung, L. E. Fein, V. F. Chan, J. Jassem, X. B. Pivot, J. V. Klimovsky, F. H. de Mendoza, et al.
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., November 20, 2007; 25(33): 5210 - 5217.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Sessa, A Perotti, A Llado, S Cresta, G Capri, M Voi, S Marsoni, I Corradino, and L Gianni
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule
Ann. Onc., September 1, 2007; 18(9): 1548 - 1553.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Thomas, J. Tabernero, M. Fornier, P. Conte, P. Fumoleau, A. Lluch, L. T. Vahdat, C. A. Bunnell, H. A. Burris, P. Viens, et al.
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
J. Clin. Oncol., August 10, 2007; 25(23): 3399 - 3406.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Vansteenkiste, P. N. Lara Jr, T. Le Chevalier, J.-L. Breton, P. Bonomi, A. B. Sandler, M. A. Socinski, C. Delbaldo, B. McHenry, D. Lebwohl, et al.
Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy
J. Clin. Oncol., August 10, 2007; 25(23): 3448 - 3455.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Roche, L. Yelle, F. Cognetti, L. Mauriac, C. Bunnell, J. Sparano, P. Kerbrat, J.-P. Delord, L. Vahdat, R. Peck, et al.
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy
J. Clin. Oncol., August 10, 2007; 25(23): 3415 - 3420.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Denduluri, J. A. Low, J. J. Lee, A. W. Berman, J. M. Walshe, U. Vatas, C. K. Chow, S. M. Steinberg, S. X. Yang, and S. M. Swain
Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes
J. Clin. Oncol., August 10, 2007; 25(23): 3421 - 3427.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni
Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs
J. Clin. Oncol., August 10, 2007; 25(23): 3389 - 3391.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist, July 1, 2007; 12(7): 785 - 797.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Cortes and J. Baselga
Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones
Oncologist, March 1, 2007; 12(3): 271 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Mani, H. McDaid, A Grossman, F Muggia, S Goel, T Griffin, D Colevas, S. Horwitz, and M. Egorin
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
Ann. Onc., January 1, 2007; 18(1): 190 - 195.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Lee, J. A. Low, E. Croarkin, R. Parks, A. W. Berman, N. Mannan, S. M. Steinberg, and S. M. Swain
Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone
J. Clin. Oncol., May 1, 2006; 24(13): 2084 - 2091.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Lee and S. M. Swain
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
J. Clin. Oncol., April 1, 2006; 24(10): 1633 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. B. Wedam, J. A. Low, S. X. Yang, C. K. Chow, P. Choyke, D. Danforth, S. M. Hewitt, A. Berman, S. M. Steinberg, D. J. Liewehr, et al.
Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
J. Clin. Oncol., February 10, 2006; 24(5): 769 - 777.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. de Jonge and J. Verweij
The Epothilone Dilemma
J. Clin. Oncol., December 20, 2005; 23(36): 9048 - 9050.
[Full Text] [PDF]

Home page
 JCOHome page
M. Hussain, C. M. Tangen, P. N. Lara Jr, U. N. Vaishampayan, D. P. Petrylak, A. D. Colevas, W. A. Sakr, and E. D. Crawford
Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111
J. Clin. Oncol., December 1, 2005; 23(34): 8724 - 8729.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online